CsA and cyclosporine derivatives, suchas Alisporivir, however are more straightforward to track and havebecome attractive candidates to treat COVID-19.43 Disruption of the cyclophilin A–N-proteoform interactionsshown here provides a convenient means of screening potential inhibitorsfor hit-to-lead optimization. The gene discussed is PPIA; the disease is COVID-19.